The Role of Tumor Necrosis Factor-α in the Pathogenesis of Vitiligo

[1]  O. Stojadinović,et al.  Clinical application of growth factors and cytokines in wound healing , 2014, Wound repair and regeneration : official publication of the Wound Healing Society [and] the European Tissue Repair Society.

[2]  G. Imokawa,et al.  Paracrine cytokine mechanisms underlying the hyperpigmentation of seborrheic keratosis in covered skin areas , 2013, The Journal of dermatology.

[3]  M. Dwivedi,et al.  Decreased regulatory T‐cells and CD4+/CD8+ ratio correlate with disease onset and progression in patients with generalized vitiligo , 2013, Pigment cell & melanoma research.

[4]  F. Salaffi,et al.  Immunogenicity and autoimmunity during anti-TNF therapy. , 2013, Autoimmunity reviews.

[5]  S. Jeon,et al.  Endothelin‐1 enhances the proliferation of normal human melanocytes in a paradoxical manner from the TNF‐α‐inhibited condition, but tacrolimus promotes exclusively the cellular migration without proliferation: a proposed action mechanism for combination therapy of phototherapy and topical tacrolimus , 2013, Journal of the European Academy of Dermatology and Venereology : JEADV.

[6]  S. Orlow,et al.  IL-17 and TNF synergistically modulate cytokine expression while suppressing melanogenesis: potential relevance to psoriasis , 2013, The Journal of investigative dermatology.

[7]  M. Mansuri,et al.  Vitiligo: interplay between oxidative stress and immune system , 2013, Experimental dermatology.

[8]  L. French,et al.  TNF-α and IFN-γ are potential inducers of Fas-mediated keratinocyte apoptosis through activation of inducible nitric oxide synthase in toxic epidermal necrolysis. , 2013, The Journal of investigative dermatology.

[9]  M. Fawzi,et al.  Basic fibroblast growth factor and tumour necrosis factor alpha in vitiligo and other hypopigmented disorders: suggestive possible therapeutic targets , 2013, Journal of the European Academy of Dermatology and Venereology : JEADV.

[10]  M. Dwivedi,et al.  Increased Tumor Necrosis Factor (TNF)-α and Its Promoter Polymorphisms Correlate with Disease Progression and Higher Susceptibility towards Vitiligo , 2012, PloS one.

[11]  Yeon-Ah Lee,et al.  A Case of Development of Vitiligo Followed by TNF-α Antagonist Treatment for Rheumatoid Arthritis , 2012 .

[12]  H. Gamil,et al.  Over-expression of tumor necrosis factor-α in vitiligo lesions after narrow-band UVB therapy: an immunohistochemical study , 2012, Archives of Dermatological Research.

[13]  J. Ocampo-Candiani,et al.  Tumor necrosis factor-α -308G/A polymorphism is associated with active vitiligo vulgaris in a northeastern Mexican population. , 2012, Experimental and therapeutic medicine.

[14]  Ai-Young Lee.  Role of Keratinocytes in the Development of Vitiligo , 2012, Annals of dermatology.

[15]  K. Alghamdi,et al.  Treatment of generalized vitiligo with anti-TNF-α Agents. , 2012, Journal of drugs in dermatology : JDD.

[16]  T. Naka,et al.  Dysregulation of melanocyte function by Th17‐related cytokines: significance of Th17 cell infiltration in autoimmune vitiligo vulgaris , 2012, Pigment cell & melanoma research.

[17]  G. Erf,et al.  IFN-gamma, IL-21 and IL-10 co-expression in evolving autoimmune vitiligo lesions of Smyth line chickens , 2011, The Journal of investigative dermatology.

[18]  S. Singh,et al.  Serum concentration of IL-6, IL-2, TNF-α, and IFNγ in Vitiligo patients , 2012, Indian journal of dermatology.

[19]  R. Sánchez-Porras,et al.  Immunopathogenesis of vitiligo. , 2011, Autoimmunity reviews.

[20]  K. Eskandar,et al.  Association of interferon-gamma (IFN-γ) and tumor necrosis factor alpha (TNF-α) polymorphisms with susceptibility to vitiligo in Iranian patients , 2011 .

[21]  K. Alghamdi,et al.  Worsening of Vitiligo and Onset of New Psoriasiform Dermatitis following Treatment with Infliximab , 2011, Journal of cutaneous medicine and surgery.

[22]  N. Yu,et al.  RNA released from necrotic keratinocytes upregulates intercellular adhesion molecule-1 expression in melanocytes , 2011, Archives of Dermatological Research.

[23]  D. Torchia,et al.  Tumor necrosis factor-α in vitiligo: direct correlation between tissue levels and clinical parameters , 2011, Cutaneous and ocular toxicology.

[24]  S. Alsurayei,et al.  Vitiligo in a patient receiving infliximab for refractory ulcerative colitis. , 2011, Arab journal of gastroenterology : the official publication of the Pan-Arab Association of Gastroenterology.

[25]  R. Lahita,et al.  Vasculitis, Vitiligo, Thyroiditis, and Altered Hormone Levels After Anti-Tumor Necrosis Factor Therapy , 2011, The Journal of Rheumatology.

[26]  S. Glassman.  Vitiligo, reactive oxygen species and T-cells. , 2011, Clinical science.

[27]  K. Alghamdi,et al.  Alghamdi KM, Khurrum H, Rikabi A.Worsening of vitiligo and onset of new psoriasiform dermatitis following treatment with infliximab. J Cutan Med Surg 15:280-284 , 2011 .

[28]  S. Mocellin,et al.  The dual role of tumor necrosis factor (TNF) in cancer biology. , 2010, Current Medicinal Chemistry.

[29]  P. Sfikakis,et al.  TNF-α antagonists beyond approved indications: stories of success and prospects for the future. , 2010, QJM : monthly journal of the Association of Physicians.

[30]  E. Dellambra,et al.  Vitiligo: pathogenetic hypotheses and targets for current therapies. , 2010, Current drug metabolism.

[31]  Ronglih Liao,et al.  The Paradoxical Role of Inflammation in Cardiac Repair and Regeneration , 2010, Journal of cardiovascular translational research.

[32]  C. Cámara-Lemarroy,et al.  Molecular Inflammatory Mediators in Peripheral Nerve Degeneration and Regeneration , 2010, Neuroimmunomodulation.

[33]  A. Offidani,et al.  A Patient with Psoriasis and Vitiligo Treated with Etanercept , 2010, American journal of clinical dermatology.

[34]  D. Bani,et al.  Keratinocyte dysfunction in vitiligo epidermis: cytokine microenvironment and correlation to keratinocyte apoptosis. , 2009, Histology and histopathology.

[35]  T. Gao,et al.  Use of anti-tumor necrosis factor agents: a possible therapy for vitiligo. , 2009, Medical hypotheses.

[36]  A. Drosos,et al.  Immune-mediated skin lesions in patients treated with anti-tumour necrosis factor alpha inhibitors , 2009, Scandinavian journal of rheumatology.

[37]  J. Auböck,et al.  Lymphocyte imbalance in vitiligo patients indicated by elevated CD4+/CD8+ T-cell ratio , 2009, Wiener Medizinische Wochenschrift.

[38]  C. Young,et al.  Reactive oxygen species in tumor necrosis factor-alpha-activated primary human keratinocytes: implications for psoriasis and inflammatory skin disease. , 2008, The Journal of investigative dermatology.

[39]  Olivera Stojadinovic,et al.  PERSPECTIVE ARTICLE: Growth factors and cytokines in wound healing , 2008, Wound repair and regeneration : official publication of the Wound Healing Society [and] the European Tissue Repair Society.

[40]  D. I. Smith,et al.  Vitiligo after the resolution of psoriatic plaques during treatment with adalimumab. , 2008, Journal of the American Academy of Dermatology.

[41]  R. Burgos-Vargas,et al.  Vitiligo Improvement in a Patient with Ankylosing Spondylitis Treated with Infliximab , 2008, Dermatology.

[42]  V. Werth,et al.  TNF-α production in the skin , 2008, Archives of Dermatological Research.

[43]  S. Shahbaz,et al.  Association of interferon-gamma and tumor necrosis factor alpha polymorphisms with susceptibility to vitiligo in Iranian patients , 2008, Archives of Dermatological Research.

[44]  Songhee Jeon,et al.  Impaired PI3K/Akt Activation-Mediated NF-κB Inactivation Under Elevated TNF-α Is More Vulnerable to Apoptosis in Vitiliginous Keratinocytes , 2007 .

[45]  S. Gregoriou,et al.  Etanercept in the Treatment of Vitiligo , 2007, Dermatology.

[46]  Songhee Jeon,et al.  Impaired PI3K/Akt activation-mediated NF-kappaB inactivation under elevated TNF-alpha is more vulnerable to apoptosis in vitiliginous keratinocytes. , 2007, The Journal of investigative dermatology.

[47]  U. Kisa,et al.  Increased tumor necrosis factor alpha (TNF‐α) and interleukin 1 alpha (IL1‐α) levels in the lesional skin of patients with nonsegmental vitiligo , 2006 .

[48]  M. Erdal,et al.  Lack of association with TNF-α-308 promoter polymorphism in patients with vitiligo , 2006, Archives of Dermatological Research.

[49]  M. Erdal,et al.  Lack of association with TNF-alpha-308 promoter polymorphism in patients with vitiligo. , 2006, Archives of dermatological research.

[50]  U. Kisa,et al.  Increased tumor necrosis factor alpha (TNF-alpha) and interleukin 1 alpha (IL1-alpha) levels in the lesional skin of patients with nonsegmental vitiligo. , 2006, International journal of dermatology.

[51]  Mohammad Z Zailaie.  Decreased proinflammatory cytokine production by peripheral blood mononuclear cells from vitiligo patients following aspirin treatment. , 2005, Saudi medical journal.

[52]  R. Boissy,et al.  4-Tertiary butyl phenol exposure sensitizes human melanocytes to dendritic cell-mediated killing: relevance to vitiligo. , 2005, The Journal of investigative dermatology.

[53]  J. Ortonne,et al.  Physiopathology and genetics of vitiligo. , 2005, Journal of autoimmunity.

[54]  C. Garbe,et al.  Tumour necrosis factors and several interleukins inhibit the growth and modulate the antigen expression of normal human melanocytes in vitro , 2005, Archives of Dermatological Research.

[55]  M. Khaled,et al.  PI3K mediates protection against TRAIL-induced apoptosis in primary human melanocytes , 2004, Cell Death and Differentiation.

[56]  D. Tobin,et al.  Melanin pigmentation in mammalian skin and its hormonal regulation. , 2004, Physiological reviews.

[57]  R. Morris,et al.  Topical tacrolimus therapy for vitiligo: therapeutic responses and skin messenger RNA expression of proinflammatory cytokines. , 2004, Journal of the American Academy of Dermatology.

[58]  G. Ogg,et al.  Immunopolarization of CD4+ and CD8+ T Cells to Type-1–Like is Associated with Melanocyte Loss in Human Vitiligo , 2003, Laboratory Investigation.

[59]  K. Wakamatsu,et al.  Effects of melanogenesis-inducing nitric oxide and histamine on the production of eumelanin and pheomelanin in cultured human melanocytes. , 2003, Pigment cell research.

[60]  Xiran Lin,et al.  Increased interleukin-6 and granulocyte-macrophage colony stimulating factor levels in the sera of patients with non-segmental vitiligo. , 2003, Journal of dermatological science.

[61]  H. Skelton,et al.  Death receptors and their role in dermatology, with particular focus on tumor necrosis factor‐related apoptosis‐inducing ligand receptors , 2003, International journal of dermatology.

[62]  J. Eberle,et al.  The Role of Nuclear Factor-kappaB and Melanogenesis in Tumor Necrosis Factor-Alpha-Induced Apoptosis of Normal Human Melanocytes , 2002, Skin Pharmacology and Physiology.

[63]  S. Moretti,et al.  New insights into the pathogenesis of vitiligo: imbalance of epidermal cytokines at sites of lesions. , 2002, Pigment cell research.

[64]  G. Imokawa,et al.  The mechanism of hyperpigmentation in seborrhoeic keratosis involves the high expression of endothelin‐converting enzyme‐1α and TNF‐α, which stimulate secretion of endothelin 1 , 2001 .

[65]  R. Beyaert,et al.  Crosstalk between NF-kappaB-activating and apoptosis-inducing proteins of the TNF-receptor complex. , 2001, Molecular cell biology research communications : MCBRC.

[66]  F. Solano,et al.  Inhibition of melanogenesis in response to oxidative stress: transient downregulation of melanocyte differentiation markers and possible involvement of microphthalmia transcription factor. , 2001, Journal of cell science.

[67]  L. Guillo,et al.  Lipopolysaccharide and cytokines induce nitric oxide synthase and produce nitric oxide in cultured normal human melanocytes , 2001, Archives of Dermatological Research.

[68]  G. Imokawa,et al.  The mechanism of hyperpigmentation in seborrhoeic keratosis involves the high expression of endothelin-converting enzyme-1alpha and TNF-alpha, which stimulate secretion of endothelin 1. , 2001, The British journal of dermatology.

[69]  F. Solano,et al.  Regulation of the murine silver locus product (gp87) by the hypopigmenting cytokines TGF-beta1 and TNF-alpha. , 2000, Pigment cell research.

[70]  J. Hallenbeck,et al.  Dual role of tumor necrosis factor alpha in brain injury. , 1999, Cytokine & growth factor reviews.

[71]  R. Buscà,et al.  Tumor necrosis factor alpha-mediated inhibition of melanogenesis is dependent on nuclear factor kappa B activation , 1999, Oncogene.

[72]  Hedley,et al.  Vitiligo melanocytes in long‐term culture show normal constitutive and cytokine‐induced expression of intercellular adhesion molecule‐1 and major histocompatibility complex class I and class II molecules , 1998, The British journal of dermatology.

[73]  Inoue,et al.  Modulation of melanocyte‐stimulating hormone receptor expression on normal human melanocytes: evidence for a regulatory role of ultraviolet B, interleukin‐1α, interleukin‐1β, endothelin‐1 and tumour necrosis factor‐α , 1998 .

[74]  F. Solano,et al.  Mechanisms of melanogenesis inhibition by tumor necrosis factor-alpha in B16/F10 mouse melanoma cells. , 1998, European journal of biochemistry.

[75]  A. Chakraborty,et al.  Modulation of melanocyte-stimulating hormone receptor expression on normal human melanocytes: evidence for a regulatory role of ultraviolet B, interleukin-1alpha, interleukin-1beta, endothelin-1 and tumour necrosis factor-alpha. , 1998, The British journal of dermatology.

[76]  Chieh-Shan Wu,et al.  Alterations in IL-6, IL-8, GM-CSF. TNF-α, and IFN-γ Release by Peripheral Mononuclear Cells in Patients with Active Vitiligo , 1997 .

[77]  C. Yu,et al.  Alterations in IL-6, IL-8, GM-CSF, TNF-alpha, and IFN-gamma release by peripheral mononuclear cells in patients with active vitiligo. , 1997, The Journal of investigative dermatology.

[78]  P. Cerutti,et al.  The roles of hydrogen peroxide and superoxide as messengers in the activation of transcription factor NF-kappa B. , 1995, Chemistry & biology.

[79]  G. Stingl,et al.  In vivo cytokine expression in normal and perturbed murine skin--analysis by competitive quantitative polymerase chain reaction. , 1993, The Journal of investigative dermatology.

[80]  J. Morelli,et al.  Influence of inflammatory mediators and cytokines on human melanocyte function. , 1993, The Journal of investigative dermatology.

[81]  V. Swope,et al.  Interleukins 1α and 6 and tumor necrosis factor-α are paracrine inhibitors of human melanocyte proliferation and melanogenesis , 1991 .

[82]  V. Swope,et al.  Interleukins 1 alpha and 6 and tumor necrosis factor-alpha are paracrine inhibitors of human melanocyte proliferation and melanogenesis. , 1991, The Journal of investigative dermatology.

[83]  D. Norris,et al.  Cytokine modulation of adhesion molecules in the regulation of immunologic cytotoxicity of epidermal targets. , 1990, The Journal of investigative dermatology.

[84]  G. Habermehl,et al.  Human fibroblasts release reactive oxygen species in response to interleukin-1 or tumour necrosis factor-alpha. , 1989, The Biochemical journal.